...
首页> 外文期刊>Annals of surgical oncology >Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ
【24h】

Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ

机译:在核心活检诊断原位的核心活检诊断之后,评估升级到侵袭性乳腺癌和/或导管癌的速率

获取原文
获取原文并翻译 | 示例

摘要

BackgroundA diagnosis of non-classic lobular carcinoma in situ (NC-LCIS) encompasses a variety of lesions with poorly characterized natural history. We evaluated upgrade rates and factors associated with upgrade to malignancy following a core biopsy diagnosis of NC-LCIS, and its natural history.MethodsUpon Institutional Review Board approval, pathology databases were searched for NC-LCIS core biopsy diagnoses (carcinoma in situ [CIS], CIS with ductal and lobular features [CIS/DLF], pleomorphic LCIS [P-LCIS], variant LCIS [V-LCIS], LCIS with necrosis). Cases with available core and excision pathology were included, while cases with concurrent ipsilateral invasive carcinoma (IC), ductal carcinoma in situ (DCIS), and/or atypical ductal hyperplasia were excluded.ResultsOverall, 121 NC-LCIS cases were identified from 1998 to 2017. We excluded 46 cases with concurrent cancer; 75 patients with 76 NC-LCIS core biopsy diagnoses followed by excision formed our study cohort. Median age was 56years (range 41-83), and all imaging findings were classified as Breast Imaging Reporting and Data System 4; calcifications were the most common biopsy indication (80%). Excision yielded malignancy in 27 (36%) patients (IC 17, 63%; DCIS alone 10, 37%). We were unable to identify radiologic or pathologic features predictive of upgrade. Of 49 pure NC-LCIS cases, 15 (31%) had mastectomy, 9 (18%) had excision and radiation, and 25 (51%) had excision alone. At a median follow-up of 58months (range 1-224), 1/25 (4%) patients with excision alone developed ipsilateral DCIS 14months later.ConclusionsIn this series of NC-LCIS, 36% of cases were upgraded, supporting routine excision. We were unable to identify predictors of upgrade. Among 25 patients with pure NC-LCIS, only one patient developed a future ipsilateral cancer. Further study of the natural history of NC-LCIS is warranted.
机译:Backgrounda诊断原位(NC-LCIS)的非经典小叶癌的诊断包括具有较差的自然历史的各种病变。在核心活检诊断NC-LCIS的核心活检诊断后,评估了与升级到恶性肿瘤相关的升级率和因素,以及其自然历史.Thiodsupon机构审查委员会批准,搜查了病理数据库的NC-LCIS核心活检诊断(原位癌[顺式] ,CIS,具有导管和叶形特征[CIS / DLF],亲属LCIS [P-LC],变体LCIS [V-LC],LCIS,具有坏死)。包括可用核心和切除病理学的病例,而患有并发的同侧侵入性癌(IC),原位(DCIS)的病例(DCIS)和/或非典型导管增生,则为1998年从1998年确定了121个NC-LCIS病例。 2017年。我们排除了46例并发癌症; 75例患有76个NC-LCIS核心活检诊断的患者,然后切除了我们的研究队列。中位年龄为56年(范围41-83),所有成像发现被归类为乳房成像报告和数据系统4;钙化是最常见的活组织检查指示(80%)。切除在27例(36%)患者中产生恶性肿瘤(IC 17,63%; DCIS仅10,37%)。我们无法识别预测升级的放射理学或病理特征。在49例纯NC-LCIS病例中,15(31%)含有乳房切除术,9(18%)有切除和辐射,25(51%)单独切除切除。在58个月(范围1-224的范围)的中间随访中,单独切除的1/25(4%)患者开发了IpsilateLal DCIS 14个月。结论该系列NC-LCIS,36%的病例升级,支持常规切除。我们无法识别升级的预测因素。在25例纯NC-LCIS中,只有一名患者开发了未来的同侧癌症。有必要进一步研究NC-LCIS的自然历史。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号